Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCORPION study of docetaxel plus ramucirumab after platinum chemotherapy plus immune checkpoint inhibitor failure in non-small cell lung cancer
jRCTs041190077Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate. Started Jan 2020; status: completed.
02
Drugs
docetaxelramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041190077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190077.